Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Acquisition Of Therakos, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Mallinckrodt (MNK) Ratings Affirmed by Moody's Following Therakos Acquisition Announcement
August 11, 2015 12:09 PM EDTMoody's Investors Service affirmed the ratings of Mallinckrodt (NYSE: MNK) ("Mallinckrodt") including the Ba3 Corporate Family Rating and the Ba3-PD Probability of Default Rating. The rating action follows the announcement that Mallinckrodt will acquire Therakos, Inc. for $1.325 billion in cash. The outlook is stable.
Moody's will evaluate the impact, if any, on the instrument ratings when the final financing terms are announced.
Moody's affirmed the following ratings of Mallinckrodt International Finance S.A.:
Corporate Family Rating, at Ba3
Probability of Default Rating, at Ba3-PD
Senior Secured Bank Credit... More
Mallinckrodt (MNK) to Acquire Therakos in $1.33B Deal
August 10, 2015 6:05 AM EDTMallinckrodt (NYSE: MNK) announced that it has entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion. Subject to customary closing conditions, the parties expect the transaction to be completed in the latter part of the third calendar quarter of 2015, Mallinckrodt's fourth fiscal quarter.
Therakos, Inc. is the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP), and is focused on providing innovative treatment platforms that harness the power of patients' immune systems to... More
